|
Daily Medical Update
Male hypogonadism
Tuesday, September 15, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
The journal of sexual medicine (2026) - Systematic Review/Network Meta-Analysis
Key Findings
- TRT plus structured lifestyle therapy produced the largest estimated increase in total testosterone versus usual care/placebo (MD 7.19; 95% CI 1.18–13.21), followed by endogenous testosterone restoration therapy (MD 4.14; 95% CI 0.74–7.54) and TRT (MD 2.53; 95% CI 0.26–4.81).
- TRT plus lifestyle therapy improved International Index of Erectile Function scores (MD 1.29; 95% CI 0.07–2.50), while TRT reduced waist circumference and increased lean mass.
- No intervention significantly reduced HbA1c; TRT increased hematocrit, and no significant between-group differences in adverse events were detected.
📋 Practice Implication: In obese men with functional hypogonadism, treatment should be individualized around weight, sexual function, and body-composition goals; lifestyle therapy may add benefit to TRT, with hematocrit monitoring and no expectation of glycemic improvement.
|
Cells (2026) - Systematic Review
Key Findings
- In men with obesity, type 2 diabetes, or functional hypogonadism, GLP-1 receptor agonists were associated with modest increases in testosterone.
- The review also found improvements in erectile function or selected semen parameters among metabolically compromised populations.
- A placebo-controlled crossover trial in healthy eugonadal men found no significant endocrine or reproductive effects and no improvement in those outcomes.
📋 Practice Implication: GLP-1 receptor agonists may support a metabolic-first strategy when obesity or diabetes contributes to functional hypogonadism, but their reproductive benefit should not be extrapolated to healthy eugonadal men and remains to be confirmed prospectively.
|
Medical sciences (Basel, Switzerland) (2026) - Systematic Review
Key Findings
- Across eight trials, the most consistent findings were increased lean mass and reduced fat mass with TRT.
- Improvement in insulin resistance was reported in several trials but was heterogeneous.
- Evidence certainty was low for fat mass, lean mass, and HOMA-IR, and very low for HbA1c, fasting glucose, lipid outcomes, and long-term safety, leaving no reliable improvement estimate for these endpoints.
📋 Practice Implication: TRT should be prescribed for confirmed hypogonadism and patient-centered benefits rather than as an antidiabetic or lipid-lowering treatment; body-composition and insulin-resistance gains require cautious interpretation.
|
Archives of endocrinology and metabolism (2025) - Meta-Analysis/Systematic Review
Key Findings
- SERM therapy increased total testosterone versus placebo by 273.76 ng/dL (95% CI 191.87–355.66; p<0.01).
- Compared with placebo, LH increased by 4.66 IU/L and FSH by 4.59 IU/L (both p<0.01).
- Total testosterone showed no significant difference between SERM therapy and testosterone gel, while SERM therapy increased total testosterone more than hCG alone.
📋 Practice Implication: Clomiphene or enclomiphene offers a fertility-preserving alternative for selected men with functional hypogonadism by increasing endogenous gonadotropin signaling, making it useful when avoiding exogenous testosterone suppression is a priority.
|
American journal of cardiovascular drugs (2025) - Meta-Analysis
Key Findings
- Across 23 randomized trials involving 9,280 men, all-cause mortality was similar with TRT and placebo (RR 0.85; 95% CI 0.60–1.19; p=0.33).
- TRT did not increase cardiovascular mortality, stroke, or myocardial infarction.
- TRT increased cardiac arrhythmia incidence (RR 1.53; 95% CI 1.20–1.97; p<0.01).
📋 Practice Implication: Cardiovascular counseling can distinguish the absence of an observed excess in mortality, stroke, or myocardial infarction from the arrhythmia signal; assess baseline rhythm risk and monitor appropriately during TRT.
|
|
💡
Summary
Recent evidence supports a phenotype-specific approach to male hypogonadism: in obese men, testosterone replacement therapy (TRT) combined with lifestyle therapy produced the largest testosterone gain and improved erectile-function scores, while GLP-1 receptor agonists were associated with modest endocrine and selected reproductive benefits in metabolically compromised men. TRT may improve body composition but should not be used as an antidiabetic or lipid-lowering treatment; a cardiovascular meta-analysis found no excess mortality, myocardial infarction, or stroke but did find more cardiac arrhythmias. SERMs increased endogenous testosterone and gonadotropins versus placebo, with no significant testosterone difference versus testosterone gel, supporting fertility-preserving alternatives when clinically appropriate.
|
|